MeSH term
Frequency | Condition_Probility | Age Factors | 2 | 0.0 |
Comparative Study | 22 | 0.0 |
Female | 43 | 0.0 |
Humans | 183 | 0.0 |
Male | 44 | 0.0 |
Odds Ratio | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Aged | 12 | 0.0 |
Double-Blind Method | 4 | 0.0 |
Middle Aged | 28 | 0.0 |
Research Support, Non-U.S. Gov't | 106 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Amino Acid Sequence | 60 | 0.0 |
Animals | 65 | 0.0 |
Base Sequence | 26 | 0.0 |
Cell Line | 24 | 0.0 |
Cells, Cultured | 11 | 0.0 |
Factor VIIa/metabolism | 2 | 4.0 |
Factor X/metabolism | 2 | 3.0 |
Factor Xa/metabolism | 3 | 5.0 |
Macromolecular Substances | 3 | 0.0 |
Molecular Sequence Data | 57 | 0.0 |
Protein Structure, Secondary | 12 | 1.0 |
Thromboplastin/metabolism | 4 | 5.0 |
Adolescent | 7 | 0.0 |
Adult | 28 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Catalytic Domain | 3 | 1.0 |
DNA Mutational Analysis | 6 | 0.0 |
Hydrogen Bonding | 3 | 1.0 |
Infant | 2 | 0.0 |
Models, Molecular | 26 | 0.0 |
*Mutation | 7 | 0.0 |
Mutation, Missense | 2 | 0.0 |
Pedigree | 10 | 0.0 |
Point Mutation | 8 | 0.0 |
Protein Structure, Tertiary | 24 | 0.0 |
Sequence Deletion | 4 | 0.0 |
1-Carboxyglutamic Acid/chemistry | 5 | 55.0 |
Binding Sites | 41 | 0.0 |
Blood Coagulation Factors/*chemistry | 2 | 40.0 |
Crystallography, X-Ray | 5 | 0.0 |
Epidermal Growth Factor/chemistry | 4 | 7.0 |
Factor Xa/chemistry | 2 | 28.0 |
Models, Biological | 6 | 0.0 |
Mutation | 5 | 0.0 |
Protein Conformation | 25 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 87 | 0.0 |
Serine Endopeptidases/metabolism | 3 | 2.0 |
Cattle | 25 | 0.0 |
Circular Dichroism | 4 | 0.0 |
Hydrolysis | 4 | 0.0 |
Spectrometry, Fluorescence | 7 | 1.0 |
Anticoagulants/*metabolism | 2 | 6.0 |
Enzyme Activation | 13 | 0.0 |
Phospholipids/metabolism | 10 | 5.0 |
Protein C/genetics/*metabolism | 4 | 44.0 |
Amino Acids/metabolism | 2 | 2.0 |
Biological Markers | 2 | 0.0 |
Osteocalcin/metabolism | 2 | 7.0 |
Antibody Specificity | 6 | 0.0 |
Factor VIIIa/metabolism | 3 | 20.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Protein Binding | 29 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
Factor IX/*chemistry/*metabolism | 2 | 66.0 |
Hamsters | 10 | 0.0 |
Kinetics | 27 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 6 | 0.0 |
Substrate Specificity | 6 | 0.0 |
Transfection | 9 | 0.0 |
Blood Platelets/*metabolism | 3 | 1.0 |
Platelet Activation | 3 | 2.0 |
Follow-Up Studies | 3 | 0.0 |
Protein C/*chemistry/metabolism | 2 | 33.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Japan | 2 | 0.0 |
Child | 7 | 0.0 |
Hypoprothrombinemias/*genetics | 2 | 100.0 |
Mutation/*genetics | 2 | 0.0 |
Phenotype | 4 | 0.0 |
Sequence Alignment | 8 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Mice | 9 | 0.0 |
1-Carboxyglutamic Acid | 3 | 100.0 |
Peptide Fragments/chemistry | 5 | 2.0 |
Protein C/*chemistry | 3 | 33.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
Solutions | 3 | 1.0 |
In Vitro | 4 | 0.0 |
Rats | 5 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 9 | 0.0 |
Factor Va/*metabolism | 3 | 13.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Prothrombin/chemistry/*metabolism | 2 | 100.0 |
Protein Folding | 2 | 0.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Vitamin K/pharmacology | 3 | 15.0 |
Warfarin/pharmacology | 3 | 20.0 |
Binding Sites/genetics | 2 | 0.0 |
Child, Preschool | 3 | 0.0 |
Family Health | 2 | 0.0 |
Serine Endopeptidases/chemistry/metabolism | 2 | 40.0 |
Thromboplastin/chemistry/metabolism | 3 | 100.0 |
Allosteric Site | 2 | 7.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Calcium/metabolism | 12 | 0.0 |
Catalysis | 4 | 0.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
*Point Mutation | 3 | 0.0 |
Recombinant Proteins/chemistry/isolation & purification/metabolism | 2 | 2.0 |
Vitamin K/metabolism | 5 | 29.0 |
Factor IXa/*metabolism | 3 | 50.0 |
Factor X/*metabolism | 6 | 25.0 |
Liposomes | 2 | 0.0 |
Recombinant Proteins/metabolism | 9 | 0.0 |
*Models, Molecular | 4 | 3.0 |
Structure-Activity Relationship | 25 | 0.0 |
Blotting, Western | 9 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Phosphorylation | 2 | 0.0 |
gamma-Linolenic Acid/*pharmacology | 5 | 62.0 |
Chromatography, Affinity | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Mutagenesis | 3 | 0.0 |
Peptides/metabolism | 4 | 1.0 |
Surface Plasmon Resonance | 4 | 2.0 |
Time Factors | 9 | 0.0 |
Anticoagulants/*pharmacology | 2 | 2.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Scattering, Radiation | 3 | 2.0 |
Exons/genetics | 2 | 0.0 |
Point Mutation/*genetics | 2 | 0.0 |
Protein C/*genetics | 4 | 8.0 |
Sequence Analysis, Protein | 2 | 1.0 |
Mutation/genetics | 2 | 0.0 |
Epidermal Growth Factor | 2 | 8.0 |
Blood Coagulation/drug effects | 3 | 2.0 |
Cell Division/drug effects | 3 | 0.0 |
English Abstract | 3 | 0.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Phospholipids/*metabolism | 6 | 4.0 |
Protein C/chemistry/*metabolism | 3 | 37.0 |
*Biological Markers | 2 | 1.0 |
Warfarin/therapeutic use | 2 | 6.0 |
1-Carboxyglutamic Acid/genetics | 2 | 66.0 |
Factor X Deficiency/*genetics | 2 | 66.0 |
Heterozygote | 2 | 0.0 |
Factor Xa/*metabolism | 2 | 9.0 |
Protein Binding/genetics | 2 | 0.0 |
Swine | 2 | 0.0 |
DNA Primers | 5 | 0.0 |
*X Chromosome | 3 | 0.0 |
Crystallization | 2 | 0.0 |
Protein C/*metabolism | 2 | 1.0 |
*Computer Simulation | 2 | 2.0 |
Mutagenesis, Site-Directed | 15 | 0.0 |
Protein C/*chemistry/genetics/metabolism | 2 | 100.0 |
*Protein Conformation | 7 | 3.0 |
Neovascularization, Pathologic/*prevention & control | 2 | 3.0 |
Fluorescence | 4 | 1.0 |
Lasers | 2 | 1.0 |
Reference Values | 5 | 0.0 |
Dosage Compensation (Genetics) | 2 | 1.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
*Blood Coagulation Factors | 2 | 6.0 |
Dogs | 4 | 0.0 |
1-Carboxyglutamic Acid/*analysis | 6 | 75.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Exons | 2 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Calcium/*metabolism | 10 | 1.0 |
Factor Xa/antagonists & inhibitors/*metabolism | 2 | 33.0 |
DNA Primers/genetics | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
*Extracellular Matrix Proteins | 2 | 1.0 |
Factor IX/chemistry | 3 | 75.0 |
Membranes, Artificial | 2 | 2.0 |
Protein C/chemistry | 2 | 33.0 |
Prothrombin/chemistry | 2 | 66.0 |
Surface Properties | 2 | 1.0 |
Protein Denaturation | 3 | 1.0 |
Arginine | 4 | 4.0 |
Chimeric Proteins/chemistry/metabolism | 2 | 3.0 |
Thromboplastin/*metabolism | 6 | 3.0 |
Osteoblasts/*drug effects/metabolism | 2 | 20.0 |
Electrostatics | 3 | 2.0 |
Phospholipids/chemistry | 3 | 16.0 |
Chromatography, High Pressure Liquid | 7 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Fibroblasts | 2 | 0.0 |
Glucosephosphate Dehydrogenase/genetics | 2 | 2.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 2 | 2.0 |
Linkage (Genetics) | 3 | 0.0 |
Phosphoglycerate Kinase/genetics | 2 | 5.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
alpha-Galactosidase/genetics | 2 | 33.0 |
1-Carboxyglutamic Acid/metabolism | 2 | 66.0 |
Binding, Competitive | 3 | 0.0 |
Glycine | 2 | 2.0 |
Iodine Radioisotopes | 2 | 0.0 |
Thrombin/metabolism | 3 | 2.0 |
Calcium/metabolism/pharmacology | 2 | 6.0 |
Epidermal Growth Factor/*chemistry | 4 | 7.0 |
Ligands | 2 | 0.0 |
Thrombomodulin/*metabolism | 2 | 8.0 |
Vitamin K/*metabolism | 2 | 40.0 |
Recombinant Proteins | 3 | 0.0 |
Computer Simulation | 3 | 0.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
1-Carboxyglutamic Acid/*metabolism | 3 | 42.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Prothrombin/metabolism | 4 | 5.0 |
Blood Coagulation | 2 | 1.0 |
Kidney | 3 | 0.0 |
Phospholipids/pharmacology | 2 | 6.0 |
Chromatography, Gel | 2 | 0.0 |
*Complement Inactivators | 3 | 3.0 |
Macrophages/metabolism | 2 | 0.0 |
Brain/metabolism | 2 | 0.0 |
CHO Cells | 4 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Models, Structural | 3 | 1.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
*Glycoproteins | 2 | 0.0 |
*1-Carboxyglutamic Acid | 3 | 100.0 |
Antibodies, Monoclonal | 5 | 0.0 |
Calcium/pharmacology | 6 | 2.0 |
Factor VIII/metabolism | 2 | 2.0 |
Glycosylation | 2 | 0.0 |
Partial Thromboplastin Time | 4 | 2.0 |
Protein Engineering | 2 | 2.0 |
Factor IX/chemistry/*metabolism | 3 | 50.0 |
Magnesium/metabolism | 3 | 4.0 |
Protein Conformation/drug effects | 2 | 3.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Protein C Deficiency | 3 | 8.0 |
1-Carboxyglutamic Acid/*chemistry | 9 | 81.0 |
Chromatography, Ion Exchange | 4 | 1.0 |
Endothelium, Vascular/cytology/metabolism | 2 | 1.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
Factor IX/*chemistry/metabolism | 2 | 66.0 |
Radioimmunoassay | 2 | 0.0 |
*Protein C Deficiency | 3 | 6.0 |
Peptide Fragments/*chemistry | 3 | 9.0 |
Aged, 80 and over | 3 | 0.0 |
Factor VIIIa/*metabolism | 3 | 50.0 |
Mathematics | 2 | 1.0 |
Models, Theoretical | 2 | 1.0 |
Prothrombin Time | 2 | 1.0 |
Prothrombin/*chemistry | 2 | 66.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Endothelium, Vascular/metabolism | 2 | 0.0 |
*Protein Structure, Tertiary | 3 | 2.0 |
1-Carboxyglutamic Acid/*genetics/metabolism | 2 | 66.0 |
*Epitope Mapping | 2 | 3.0 |
Factor IX/genetics/*metabolism | 2 | 100.0 |
Blood Coagulation Factors/chemistry/metabolism | 2 | 100.0 |
Peptide Fragments/*chemistry/metabolism | 2 | 9.0 |
Prothrombin/*chemistry/metabolism | 2 | 100.0 |
Thrombin/*metabolism | 2 | 2.0 |
Calcium/*pharmacology | 2 | 2.0 |
Factor VII/*chemistry | 2 | 66.0 |
Osteocalcin/*chemistry | 2 | 100.0 |
Factor VIIa/*metabolism | 2 | 5.0 |
Heat | 2 | 0.0 |
Calcium/*metabolism/pharmacology | 3 | 11.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Liposomes/metabolism | 2 | 3.0 |
Glutamic Acid/chemistry | 2 | 5.0 |
Sequence Analysis | 2 | 0.0 |
1-Carboxyglutamic Acid/*blood | 3 | 60.0 |
Biological Markers/blood | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
Vitamin K/antagonists & inhibitors | 2 | 33.0 |
Restriction Mapping | 3 | 0.0 |
Factor Va/metabolism | 2 | 6.0 |
Glutamic Acid | 2 | 2.0 |
Molecular Weight | 2 | 0.0 |
X-Ray Diffraction | 3 | 3.0 |
Recurrence | 2 | 0.0 |
Tryptophan | 2 | 7.0 |
Factor Va/chemistry | 2 | 50.0 |
Calcium/*chemistry | 2 | 15.0 |
gamma-Linolenic Acid | 2 | 66.0 |
Factor IX/*genetics | 3 | 11.0 |
Calcitriol/blood | 2 | 4.0 |
Infant, Newborn | 2 | 0.0 |
Osteocalcin/*blood | 2 | 9.0 |
Thrombin/pharmacology | 2 | 0.0 |
Factor IX/*chemistry | 2 | 50.0 |
1-Carboxyglutamic Acid/*urine | 2 | 100.0 |
Chromatography, High Pressure Liquid/methods | 2 | 1.0 |
Alkaline Phosphatase/blood | 2 | 1.0 |
Bone and Bones/metabolism | 2 | 3.0 |
Calcium/blood | 2 | 0.0 |
Parathyroid Hormone/blood | 3 | 1.0 |
Blood Coagulation Tests | 2 | 1.0 |
Protein Processing, Post-Translational | 3 | 0.0 |
Bone and Bones/*metabolism | 2 | 2.0 |
*Dosage Compensation (Genetics) | 2 | 1.0 |
Factor Xa/*chemistry/metabolism | 2 | 50.0 |
Osteoporosis/blood/*etiology | 2 | 66.0 |
Rabbits | 2 | 0.0 |
Factor IX/*metabolism | 3 | 42.0 |
Hydroxylation | 2 | 0.0 |
Calcium-Binding Proteins/*blood | 3 | 11.0 |
Osteocalcin | 5 | 38.0 |
Glutamates/*urine | 3 | 100.0 |
Glutamates/*analysis | 3 | 75.0 |
Tissue Distribution | 3 | 0.0 |
DNA, Recombinant | 3 | 1.0 |
Variation (Genetics) | 4 | 0.0 |
Factor IXa | 2 | 66.0 |
Emulsions | 2 | 2.0 |
Fatty Acids/blood | 2 | 4.0 |
*Food, Formulated | 2 | 10.0 |
Escherichia coli | 2 | 0.0 |
4-Hydroxycoumarins/pharmacology | 2 | 100.0 |
*Carbon-Carbon Ligases | 2 | 15.0 |
DNA | 2 | 0.0 |
Electron Transport | 2 | 3.0 |
Immunologic Techniques | 2 | 0.0 |
Intestinal Absorption | 2 | 1.0 |
Ligases/isolation & purification/physiology | 2 | 100.0 |
Microsomes, Liver/enzymology | 2 | 0.0 |
Mixed Function Oxygenases/metabolism | 2 | 1.0 |
Nutritional Requirements | 2 | 6.0 |
Protein Precursors | 2 | 16.0 |
Protein Sorting Signals | 2 | 2.0 |
Prothrombin/biosynthesis/genetics/secretion | 2 | 100.0 |
Quinone Reductases/metabolism | 2 | 33.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Salicylates/pharmacology | 2 | 66.0 |
Vitamin A/pharmacology | 2 | 14.0 |
Vitamin E/pharmacology | 2 | 6.0 |
Vitamin K/antagonists & inhibitors/*physiology | 2 | 100.0 |
Vitamin K 1/analogs & derivatives/metabolism | 2 | 100.0 |
Vitamin K Deficiency/etiology | 2 | 100.0 |